AstraZeneca to buy Fusion Pharma in $2.4bln deal

AstraZeneca PLC (LSE:AZN) is acquiring clinical-stage oncology group Fusion Pharmaceuticals in a $2.4 billion (£1.9 billion) deal. The offer represents a massive 126% premium to Nasdaq-listed Fusion’s Monday closing price. AstraZeneca will pay $2 billion upfront at $21 per share followed by a contingent $3 per share “upon the achievement of a specified regulatory milestone”. Fusion “will complement AstraZeneca's leading oncology portfolio with the addition of the Fusion pipeline of RCs, including their most ...